Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Free Cash Flow: 2020-2025

Historic Free Cash Flow for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $9.6 million.

  • GeneDx Holdings' Free Cash Flow rose 284.09% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 125.99%. This contributed to the annual value of -$34.0 million for FY2024, which is 81.67% up from last year.
  • According to the latest figures from Q3 2025, GeneDx Holdings' Free Cash Flow is $9.6 million, which was up 19.18% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Free Cash Flow ranged from a high of $9.6 million in Q3 2025 and a low of -$90.4 million during Q3 2022.
  • In the last 3 years, GeneDx Holdings' Free Cash Flow had a median value of -$6.1 million in 2024 and averaged -$18.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 20,001.80% in 2021, then soared by 284.09% in 2025.
  • Quarterly analysis of 5 years shows GeneDx Holdings' Free Cash Flow stood at -$54.6 million in 2021, then fell by 19.60% to -$65.3 million in 2022, then soared by 50.66% to -$32.2 million in 2023, then spiked by 81.19% to -$6.1 million in 2024, then spiked by 284.09% to $9.6 million in 2025.
  • Its Free Cash Flow stands at $9.6 million for Q3 2025, versus $8.1 million for Q2 2025 and $4.1 million for Q1 2025.